Tyrosine kinase inhibitors as a targeted therapy for clear cell renal carcinoma: case report of the intrahepatic bile ducts
https://doi.org/10.18027/2224-5057-2015-1-49-52
Abstract
This article is a result of their own long-term observation of the patient treatment of inoperable cancer of the kidney. As first-line therapy pazopanib is used in standard dosage. The drug belongs to the new generation of drugs that block angiogenesis and having cytoreductive effect. During treatment, the stabilization of the disease. The results of treatment can be recommended for use pazopanib treatment of kidney cancer.
About the Authors
A. D. Kaprin
Medical Radiology Centre of Hertsen FMRC MH RF
Russian Federation
Russian Federation
S. A. Ivanov
Medical Radiology Centre of Hertsen FMRC MH RF
Russian Federation
Russian Federation
A. A. Klimenko
Medical Radiology Centre of Hertsen FMRC MH RF
Russian Federation
Russian Federation
N. Y. Dobrovolskaya
ГБУ « МКНЦ» ДЗГМ
Russian Federation
Russian Federation
References
1. Kaprin A.D., Starinskyj V.V., Petrova G.V. Malignant tumors in Russia in 2012. Moscow. 2014.
2. Chubenko V.A. Targeted therapy complications. RUSSCO. 2012. i.9, p.3.
3. Klimenko A.A. Use of tyrosine kinase drugs in the treatment of advanced kidney cancer. TERRA MEDICA. 2013. no.3 (73). p.37–41.
4. Motzer R. J., Masumdar M., Bacic J.et al. Survival and prognostic stratification of 670 patients with advanced renal cell сarcinoma. J Clin Oncol. 1999;17 (8):2530–40.
5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer [v.1.2009].Available at physician_ gls/PDF/kidney.pdf
6. Farrell M. A., Di Marco D. C. Imaging-guided radiofrequency ablation of solid renal tumors // AJR Amer. J. Roentgenol.— 2003.— Vol.180.— P.1509.
7. Giberti C., Oneto F., Martorana G. et al. Radical nephrectomy for renal cell carcinoma: long-term results and prognostic factors on a series of 328 cases // Eur. Urol. 1997. Vol. 31. № 1. P. 40–48
8. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061–8.
9. McCann L, Amit O, Pandite L, Amado RG. An indirect comparison analysis of pazopanib versus other agents in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2010;28: Suppl: e15128. abstract.
Review
For citations:
Kaprin A.D., Ivanov S.A., Klimenko A.A., Dobrovolskaya N.Y. Tyrosine kinase inhibitors as a targeted therapy for clear cell renal carcinoma: case report of the intrahepatic bile ducts. Malignant tumours. 2015;(1):54-58. (In Russ.) https://doi.org/10.18027/2224-5057-2015-1-49-52
Views:
1106
Email this article 